Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Semaglutide wins 1 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Lixisenatide and Semaglutide have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-directed. Subcutaneous 20 µg once daily within the hour before the first meal of the day, after a 10 µg starting dose for 14 days. DO NOT self-dose.
morning
Subcutaneous once-daily injection (Adlyxin / Lyxumia)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
Weeks (24-week endpoints)
Per meal / weeks
Months
Median 25 months
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA).
N Engl J Med (2015) · Rct · n=6068
Cardiovascular-outcomes RCT: 6,068 patients with type 2 diabetes and a recent acute coronary syndrome (MI or unstable angina within 180 days), lixisenatide vs placebo added to usual care, median 25 months
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Diabetes Care (2012) · Rct · n=361
Phase-3 double-blind 12-week RCT, 361 drug-naive patients with type 2 diabetes randomized to lixisenatide (two titration regimens) or placebo
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Diabetes Care (2013) · Rct · n=495
Phase-3 double-blind RCT, 495 patients on established basal insulin with inadequate control, add-on lixisenatide 20 µg vs placebo for 24 weeks
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 1 of 3 categories.
No known interactions between Lixisenatide and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.